September 14, 2020

SARS-CoV-2 Antibody Prevalence and Association with Routine Laboratory Values in a Life Insurance Applicant Population

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): antibodies

• [Preprint, not peer-reviewed] Testing for SARS-CoV-2 antibodies indicates that the total number of SARS-CoV-2 infections in the US is 3.8-times higher than the total number of cases reported to the CDC. This estimate is based on a seropositivity rate of 3% among 50,130 consecutive life insurance applicants, which would correspond to 6.98 million SARS-CoV-2 infections when applied to state population data from the US Census as of June 1, 2020.

Rigatti et al. (Sept 11, 2020). SARS-CoV-2 Antibody Prevalence and Association with Routine Laboratory Values in a Life Insurance Applicant Population. Pre-print downloaded September 14 from https://doi.org/10.1101/2020.09.09.20191296